STOCKS TELEGRAPH

Tag: Vertex Pharmaceuticals

  • 7 Biotech Stocks to Buy in 2021

    7 Biotech Stocks to Buy in 2021

    Change is inevitable in every aspect of life because it results from human exploration and applying knowledge to improve life quality. This is why many industries have shown significant growth with time, and the biotech industry is one of them. The biotech industry has extraordinarily impacted healthcare, biological science, economy, and business in recent years. The plethora of biotech stocks continuously put their efforts into developing therapeutics and vaccines that are effective and less toxic, and easily accessible for individuals. With the rise of COVID-19, the Biotech industry has gained more importance. Many biotech stocks have developed and commercialize vaccines in the battle against the deadly pandemic. Now many investors are looking for biotech stocks to get high profits in the future. Here are the 7 biotech stocks to buy in 2021.

    Pfizer (PFE)

    The first and foremost stock to watch in 2021 is Pfizer (PFE), one of the first biotech stocks to market the COVID-19 vaccine. Since then, it has contracted with many governments and supplied millions of doses and looking forward to providing more than this in the future. The U.S government has a plan to vaccinate all of its adult population, and Pfizer is likely to contribute a lot to this cause. While many other biotech stocks only focus on older patients, Pfizer is also developing a COVID-19 vaccine for children, which is another positive sign for future growth. The company has a market cap of more than $220 billion and annual revenue of more than $40 billion. Hence Pfizer stock can be a good bet in 2021. 

    Regeneron Pharmaceuticals (REGN)

    The second stock that could prove fruitful for investors in 2021 is Regeneron Pharmaceuticals(REGN). The company has a market cap of more than $55 billion and is engaged in discovering, developing, and manufacturing various therapeutics to treat medical conditions worldwide. One of the two authorized antibody treatments to treat COVID patients belongs to Regeneron. Its recent first-quarter results show that its quarterly revenue showed 38% growth year over year. Its COVID-19 antibody treatment alone generated $262 million in the first quarter of 2021. Besides this, Eylea, a drug to treat eye diseases, also impacts its increased sales over time. Hereafter, investors need to keep an eye on this stock.

    Novavax (NVAX)

    On Number three, we have Novavax (NVAX). It is another biotech stock engaged in the development of commercialization of vaccines to prevent infectious diseases. Novavax has significantly outperformed in the COVID-19 era and still giving a tough time to its competitors. Its COVID-19 vaccine candidate NVX-CoV2373 could bring massive profits in the future. Novavax is about to finalize the major supply deal with the European Union, which means the supply of 500 million or more doses. So, a lot of money on the line is expected for Novavax stock. 

    Moreover, it has also inked supply deals with many countries in which India is also included, which has more than 1.3 billion population. Novavax generated a breathtaking $447 million in revenue in the first quarter of 2021 compared to $3 million in the same quarter of last year. This significantly increased revenue shows its success over the year. In a nutshell, investors should keep an eye on this stock.

    Bio N Tech SE (BNTX)

    On Number four, we have Bio N Tech (BNTX), which is a biotechnology company engaged in discovering and developing therapeutics to treat various infectious diseases. Bio N Tech is the partner of Pfizer in the battle against COVID-19. BNTX stock expects $26 billion in sales for the COVID-19 vaccine and its partner in 2021 and estimates roughly $3 billion in earnings. Millions of the mutually prepared COVID-19 vaccine doses have been delivered to many countries so far. Both partners are negotiating with many other countries to supply COVID-19 vaccine doses worth $3 billion by 2022, which points to the bright future of BioNTech stock. So it can be a good bet for investors in the future.

    Ocugen (OCGN)

    Ocugen (OCGN), stands at number five on our list. It is a clinical-stage biopharmaceutical company focused on developing therapeutics to cure blindness and other retinal diseases. Ocugen stock is working with Bharat Biotech to develop COVAXIN and the vaccine used to treat COVID patients. The phase-3 study results of COVIXIN showed 100% efficacy against severe coronavirus and 78% efficacy against mild and moderate COVID-19 disease. The Indian government has given emergency use authorization to Bharat Biotech which is a positive sign for Ocugen stock. Ocugen stock is looking forward to developing the COVID-19 vaccine for other markets and can be a good bet for investors in the future.

    Seagen (SGEN) 

    Seagen Inc is an American-based biotech stock focused on developing and commercializing therapeutics to treat cancer patients, and it’s in the Number six position on our list. Seagen has shown significant growth in 2020 as compared to 2019. Its revenue for 2020 totaled $2.2 billion, which shows 140% growth over the year. The revenue for the year 2019 was $916.7 billion. The company has achieved global success with Adcetris, an antibody medicine used to treat lymphoma, and is in an excellent position to invest more in developing newer medications. Therefore, Seagen is one of the biotech stocks to watch in 2021.

    Vertex Pharmaceuticals (VRTX)

    The seventh biotech stock to watch in 2021 is Vertex Pharmaceuticals Incorporated (VRTX), which is mainly focused on developing and commercializing therapeutics to treat cystic fibrosis. Trikafta is the most important drug of Vertex pharmaceutical that treats roughly 90% of patients with cystic fibrosis. Estimates show that 70,000 cystic fibrosis patients are there globally, and Trikafta is the only medication available for this disease. Vertex stock has generated significant revenue through Trikafta and some other products, which will continue to rise in the future. The company has partnered with CRISPR Therapeutics and announced impressive results from a clinical trial of gene therapy for two rare blood diseases. Consequently, its continued success against cystic fibrosis and clinical developments suggests that this stock could outperform in the long run.

    The following three biotech stocks are with the lowest 12-month trailing price-to-earnings ‎ratio (P/E). Dividends and buybacks are two ways a company can return profits to ‎shareholders, so a low P/E ratio shows you are paying less for every dollar of profits ‎generated.

    The Agios Pharmaceuticals (AGIO)‎

    The Agios Pharmaceuticals Inc. platform is a pharmaceutical company dedicated to ‎developing drugs for genetic diseases such as hemolytic anemias and sickle cell disease. In Q1 ‎‎2021, the company reported a net income of $1.9 billion, a far cry from its Q1 2020 loss. ‎Agios’ oncology portfolio was sold to Servier Pharmaceuticals LLC in the first quarter, which ‎had an impact on revenue.

    Sage Therapeutics, Inc.. (SAGE)

    Sage Therapeutics has developed treatment for issues related the central nervous system, including schizophrenia and major depression. The company reported positive results from its SAGE-718 clinical trial, a drug that may be used to treat Huntington disease, in Q1 2021.

    Innoviva Inc. (INVA)

    Innoviva is a healthcare-oriented asset manager that holds portfolios of royalties for many pharmaceuticals.

  • The Three Top Healthcare Stocks to Buy in 2021

    The Three Top Healthcare Stocks to Buy in 2021

    The healthcare sector is a massive industry with a wide potential for investors.

    Healthcare is a basic necessity for people all over the world. Each year, we see new types of mysterious diseases that are often deadly. Such as the coronavirus is one of the broad examples of it. The global pandemic has caused more than 2.3 million deaths, and almost 107 million are facing the virus.

    Despite the health concerns, many of the health stocks made big gains. However, healthcare stocks as a whole underperformed the broader market, rising 11% compared to S&P 500 rose 15.9%. Still, the sentiment regarding healthcare stocks is high with the public health concerns. The vaccine is still in a frantic zone and many companies are still researching for more improvement.

    In that premise, healthcare is a big market and has massive potential. So, let’s have a look at the three top healthcare stocks to buy this year.

    Medtronic (MDT)

    Medtronic (MDT) is an American Irish-domiciled medical device corporation. The company generates most of its sales and profits from the US healthcare market. The healthcare firm with nearly $159 billion market value is a compelling stock for investors. Medtronic is among healthcare firms with safe, stable, and longer-term growth potential.

    Talking about Medtronic’s stability, the company is an exclusive member of the S&P dividend aristocrats list. This means that MDT is those dividend stocks that have raised their dividend payments for a consecutive 25 years long period or more. While MDT has an undisputed streak of over 43 years. 

    Medtronic has shown interest in investing in Compute Health Acquisition Corp., a blank-check company that is expected to go public—with an IPO of $750 million. The company has plans to buy almost 1.5 million units in the offering.

    Compute Health has plans to invest in the healthcare sector through the rising computing power and AI technology. This biotech healthcare is set to change the dynamics of the healthcare industry. So, Medtronic’s potential investment could be an effective one in the long-term.

    Vertex Pharmaceuticals (VRTX)

    Vertex Pharmaceuticals (VRTX) is one of the leading in the healthcare industry. The company’s primary focus remains on the development of drugs that treat the basic cause of cystic fibrosis (CF). CF is a rare genetic disease that causes lung problems and damages other organs, as well.

    The company’s most prominent drug, a 3-in-1 pill – Trikafta that obtain approval back in 2019, generated over $3.9 billion in sales for the very first year in 2020. Trikafta is anticipated to drive the company’s revenue for the next few years.

    Furthermore, Vertex’s management has indicated acquiring more assets to diversify its portfolio and accelerate its pipeline. VRTX shares are down and are expected to have an upward movement anytime soon. So, it’s one of the stocks to buy with potential upside.

    McKesson Corp. (MCK)

    McKesson Corp. (MCK) is a pharmaceutical and other healthcare products supplier and distributor. McKesson is more of a logistics firm, still, its involvement in the healthcare sector makes it a promising healthcare firm.

    The company recently reported third-quarter FY21 results which came on top with the rise in distribution services. The adjusted gross profit soared over 7% year-over-year, which was mostly driven by an incline in the distribution of COVID-19 tests. Moreover, McKesson’s work assembling ancillary supply kits for COVID-19 vaccines also played a key role in profit growth.

    The company distributed over 25 million vaccine doses of Moderna’s COVID-19 vaccine in January. The pharmaceutical distributor expects more contracts to be signed with the U.S. government for the distribution of more vaccines.   

    With this, the company has upgraded its full-year 2020 outlook and anticipates the adjusted earnings between $16.95 and $17.25 per share. So, McKesson Corp. (MCK) seems a suitable investment option with potential growth opportunity this year.

  • 3 of the Best Biotech Stocks to Buy for 2021

    3 of the Best Biotech Stocks to Buy for 2021

    Due to the spread of the coronavirus pandemic all over the world Biotech stocks have gained great attention in the market. There is great competition between biotech giants, and this makes investors confuse to predict which stock will be more fruitful for them in terms of revenue. But one should not ignore the fact that other diseases and medical challenges still exist even if they are not like that much popular as the COVID-19 is.

    Moderna Inc (NASDAQ: MRNA)

    Moderna, Inc. (MRNA) is a leading mRNA Technology platform that aims on using messenger RNA (mRNA) to produce a new generation of transformative drugs for patients.

    2020 proved to be a good year for Moderna because its share price has reached up to the mark of more than 500%.Covid-19 mRNA-1273 is mainly responsible for this rise as this vaccine has shown very effective results. Further this vaccine has gained the trust of about 30 countries’ regulatory bodies as they have approved it for use.

    According to MichaelYee, a Wall Street analyst, Moderna has already signed $11.7B in contracts in which dose range is from 510M to 525M. The company is looking forward to signing additional contracts for 2021 and 2022 where the capacity will reach up to 1.2B doses.

    Moderna has to compete with its competitors especially Pfizer and JNJ(which is going to share results 3rd trial phase of Covid-19 Vaccine shortly) to maintain its reputation but due to the very high demand for vaccine in the globe, at least five companies can sell at full capacity to fulfill the need of vaccine in the globe. Moderna has also stepped in the 2nd phase study of the age group from 12 to 17 and U.S. Food and Drug may authorize vaccine for teens which could add more value to Moderna’sannual revenue.

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

    Vertex Pharmaceutics Inc.(VRTX) is focused on discovering, developing & manufacturing small molecule drugs for the cure of cystic fibrosis, viral infections, bacterial infections, autoimmune diseases, cancer, and neurological disorders.

    The company is playing the lead role in the cure of cystic fibrosis as it is estimated that 50% of patients diagnosed with cystic fibrosis in many countries are using Vertex’s medications. Vertex’s main product is Trikafta which is approved by the FDA at the end of 2019. Trikafta has already generated $3b revenue alone and is expected to generate more in the future as the company is putting serious effort to get the approval of this product for different age groups.

    Novavax, Inc. (NASDAQ: NVAX)

    Novavax, Inc. (NVAX) is a late-stage company that aims in improved global health through the discovery, development, and commercialization of innovative vaccines to prevent infectious disease. The company’s main contributions in preventing diseases include COVID-19, seasonal influenza, RSV, Ebola, Mers, and SARS.

    The company has recently announced that it has contracted with the Government of Canada to supply 76Million doses of NVX-CoV2373, a company’s recombinant protein-based COVID-19 vaccine, to control the pandemic in the region. This contract will help the company to generate a handsome revenue in future.

    Besides the COVID-19 vaccine, the company is putting some serious effort into Nanoflu, a seasonal influenza vaccine for the olders, to influence the global influenza market which will worth more than 6Billion annually by 2026. The 3rd clinical analysis of the Nanoflu showed exceptional results and now the company is expecting to get approval from the U.S food and drug administration soon to commercialize its product and if it happens, it will further boost the company’s reputation and maximize the potential to generate billions of dollars revenue annually.